Cellumed announced on the 13th that it has decided to issue 20 billion KRW worth of publicly offered bonds with warrants (BW). The bonds have a maturity of 3 years, with a coupon rate and maturity interest rate of 3.0% and 5.0%, respectively.
According to the company, the secured funds will be used to further expand Cellumed's innovative mRNA business and secondary battery business, and to build future growth engines for the company through new investments.
The invested funds are planned to be allocated to ▲ mRNA production enzymes and protein production lines ▲ allogeneic skin based on tissue banks ▲ establishment and expansion of research and development pipelines ▲ EV and secondary battery businesses, aiming to strengthen business competitiveness and maximize sales.
More specifically, the company intends to lay the foundation for a resurgence in its core bio-medical device business by building a diverse portfolio. The protein production line will be expanded to increase production capacity, and the mRNA business is expected to gain momentum in entering the vaccine and therapeutic markets, as well as expanding the bio-medical device business.
Cellumed holds numerous patents related to BMP2. It has been recognized by the government for its technological development capabilities and was selected as a leading company in the Excellent Corporate Research Institute Development Project (ATC+), reflecting high potential.
The secondary battery business is accelerating research, development, and production of electric two-wheelers and battery packs through a partnership with BYD, a Chinese electric vehicle manufacturer. By standardizing and improving the quality of battery packs, mass production is expected to begin soon, targeting market leadership in Korea.
The Battery Swap Station (BSS) business is also progressing smoothly by strengthening technological competitiveness through in-house technology development and securing external core technology patents.
A Cellumed representative stated, "The decision to issue BW is one of the important steps to strengthen our core business and leap forward into new businesses," adding, "We will efficiently utilize the raised funds not only for mRNA vaccine production enzymes and allogeneic skin business based on tissue banks but also for the high-growth EV and secondary battery businesses to achieve visible performance growth."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
